Lifecore Cash And Short Term Investments vs Net Receivables Analysis

LFCR Stock

5.91 0.15 2.48%

Lifecore Biomedical financial indicator trend analysis is infinitely more than just investigating Lifecore Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Lifecore Biomedical is a good investment. Please check the relationship between Lifecore Biomedical Cash And Short Term Investments and its Net Receivables accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.

Cash And Short Term Investments vs Net Receivables

Cash And Short Term Investments vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Lifecore Biomedical Cash And Short Term Investments account and Net Receivables. At this time, the significance of the direction appears to have pay attention.

The correlation between Lifecore Biomedical's Cash And Short Term Investments and Net Receivables is -0.72. Overlapping area represents the amount of variation of Cash And Short Term Investments that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Lifecore Biomedical, assuming nothing else is changed. The correlation between historical values of Lifecore Biomedical's Cash And Short Term Investments and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cash And Short Term Investments of Lifecore Biomedical are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Cash And Short Term Investments i.e., Lifecore Biomedical's Cash And Short Term Investments and Net Receivables go up and down completely randomly.

Correlation Coefficient

-0.72

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Lifecore Biomedical balance sheet. This account contains Lifecore Biomedical investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Lifecore Biomedical fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Net Receivables

Most indicators from Lifecore Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Lifecore Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.At this time, Lifecore Biomedical's Selling General Administrative is relatively stable compared to the past year. As of 06/08/2024, Tax Provision is likely to grow to about 363.5 K, while Enterprise Value Over EBITDA is likely to drop 7.98.

	2021	2023	2024 (projected)
Total Revenue	185.8M	103.3M	98.1M
Interest Expense	17.4M	18.2M	19.1M

Total Revenue Interest Expense

Lifecore Biomedical fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Net Receivables	Intangible Assets	Common Stock	Current Deferred Revenue	Short Term Investments
Total Assets		0.7	0.7	0.89	0.74	0.89	0.69	0.54	0.93	-0.62	0.99	-0.73	-0.63	0.7	0.33	0.64	-0.26	0.68	0.67	0.83	0.7	0.98	0.33	-0.65	-0.47	-0.73
Short Long Term Debt Total	0.7		0.6	0.81	0.18	0.87	0.99	-0.03	0.53	-0.69	0.58	-0.71	-0.7	0.55	0.59	0.96	0.07	0.79	0.84	0.95	0.81	0.75	-0.11	-0.39	-0.24	-0.35
Other Current Liab	0.7	0.6		0.72	0.46	0.69	0.59	0.28	0.51	-0.43	0.68	-0.4	-0.44	0.65	0.27	0.57	-0.35	0.59	0.55	0.64	0.59	0.67	0.15	-0.63	-0.46	-0.67
Total Current Liabilities	0.89	0.81	0.72		0.56	0.86	0.81	0.37	0.79	-0.69	0.84	-0.7	-0.69	0.56	0.32	0.74	0.02	0.63	0.71	0.89	0.93	0.9	0.22	-0.49	-0.44	-0.58
Total Stockholder Equity	0.74	0.18	0.46	0.56		0.48	0.13	0.96	0.73	-0.43	0.81	-0.48	-0.46	0.35	-0.36	0.14	-0.27	0.22	0.01	0.37	0.43	0.71	0.62	-0.38	-0.72	-0.73
Property Plant And Equipment Net	0.89	0.87	0.69	0.86	0.48		0.86	0.25	0.72	-0.76	0.83	-0.7	-0.77	0.68	0.5	0.83	-0.09	0.84	0.79	0.9	0.77	0.89	-0.08	-0.55	-0.28	-0.52
Net Debt	0.69	0.99	0.59	0.81	0.13	0.86		-0.09	0.52	-0.73	0.57	-0.69	-0.73	0.54	0.66	0.94	0.1	0.76	0.88	0.94	0.79	0.75	-0.18	-0.4	-0.16	-0.34
Retained Earnings	0.54	-0.03	0.28	0.37	0.96	0.25	-0.09		0.57	-0.27	0.63	-0.39	-0.31	0.08	-0.58	-0.09	-0.14	-0.05	-0.24	0.13	0.29	0.5	0.68	-0.14	-0.72	-0.56
Accounts Payable	0.93	0.53	0.51	0.79	0.73	0.72	0.52	0.57		-0.41	0.95	-0.71	-0.41	0.57	0.29	0.43	-0.23	0.49	0.6	0.69	0.55	0.88	0.48	-0.57	-0.37	-0.61
Cash	-0.62	-0.69	-0.43	-0.69	-0.43	-0.76	-0.73	-0.27	-0.41		-0.56	0.56	1.0	-0.32	-0.19	-0.7	-0.22	-0.52	-0.47	-0.69	-0.73	-0.72	0.22	0.2	0.3	0.4
Non Current Assets Total	0.99	0.58	0.68	0.84	0.81	0.83	0.57	0.63	0.95	-0.56		-0.71	-0.57	0.65	0.24	0.51	-0.29	0.59	0.58	0.73	0.62	0.94	0.38	-0.63	-0.48	-0.73
Non Currrent Assets Other	-0.73	-0.71	-0.4	-0.7	-0.48	-0.7	-0.69	-0.39	-0.71	0.56	-0.71		0.57	-0.18	-0.3	-0.51	-0.25	-0.33	-0.56	-0.66	-0.61	-0.7	-0.16	0.1	0.36	0.24
Cash And Short Term Investments	-0.63	-0.7	-0.44	-0.69	-0.46	-0.77	-0.73	-0.31	-0.41	1.0	-0.57	0.57		-0.32	-0.15	-0.7	-0.22	-0.53	-0.44	-0.7	-0.74	-0.72	0.2	0.19	0.34	0.4
Common Stock Shares Outstanding	0.7	0.55	0.65	0.56	0.35	0.68	0.54	0.08	0.57	-0.32	0.65	-0.18	-0.32		0.52	0.65	-0.73	0.88	0.66	0.71	0.37	0.73	0.13	-0.97	-0.24	-0.79
Non Current Liabilities Total	0.33	0.59	0.27	0.32	-0.36	0.5	0.66	-0.58	0.29	-0.19	0.24	-0.3	-0.15	0.52		0.56	-0.12	0.59	0.89	0.54	0.16	0.33	-0.42	-0.44	0.44	-0.01
Inventory	0.64	0.96	0.57	0.74	0.14	0.83	0.94	-0.09	0.43	-0.7	0.51	-0.51	-0.7	0.65	0.56		-0.07	0.88	0.78	0.94	0.76	0.72	-0.14	-0.49	-0.24	-0.43
Other Current Assets	-0.26	0.07	-0.35	0.02	-0.27	-0.09	0.1	-0.14	-0.23	-0.22	-0.29	-0.25	-0.22	-0.73	-0.12	-0.07		-0.42	-0.09	-0.11	0.23	-0.25	-0.36	0.81	0.26	0.69
Other Stockholder Equity	0.68	0.79	0.59	0.63	0.22	0.84	0.76	-0.05	0.49	-0.52	0.59	-0.33	-0.53	0.88	0.59	0.88	-0.42		0.75	0.84	0.55	0.72	-0.12	-0.74	-0.18	-0.56
Total Liab	0.67	0.84	0.55	0.71	0.01	0.79	0.88	-0.24	0.6	-0.47	0.58	-0.56	-0.44	0.66	0.89	0.78	-0.09	0.75		0.83	0.56	0.67	-0.2	-0.56	0.11	-0.28
Total Current Assets	0.83	0.95	0.64	0.89	0.37	0.9	0.94	0.13	0.69	-0.69	0.73	-0.66	-0.7	0.71	0.54	0.94	-0.11	0.84	0.83		0.82	0.89	0.09	-0.58	-0.34	-0.57
Short Term Debt	0.7	0.81	0.59	0.93	0.43	0.77	0.79	0.29	0.55	-0.73	0.62	-0.61	-0.74	0.37	0.16	0.76	0.23	0.55	0.56	0.82		0.75	0.1	-0.26	-0.47	-0.42
Net Receivables	0.98	0.75	0.67	0.9	0.71	0.89	0.75	0.5	0.88	-0.72	0.94	-0.7	-0.72	0.73	0.33	0.72	-0.25	0.72	0.67	0.89	0.75		0.29	-0.67	-0.49	-0.77
Intangible Assets	0.33	-0.11	0.15	0.22	0.62	-0.08	-0.18	0.68	0.48	0.22	0.38	-0.16	0.2	0.13	-0.42	-0.14	-0.36	-0.12	-0.2	0.09	0.1	0.29		-0.23	-0.63	-0.5
Common Stock	-0.65	-0.39	-0.63	-0.49	-0.38	-0.55	-0.4	-0.14	-0.57	0.2	-0.63	0.1	0.19	-0.97	-0.44	-0.49	0.81	-0.74	-0.56	-0.58	-0.26	-0.67	-0.23		0.24	0.83
Current Deferred Revenue	-0.47	-0.24	-0.46	-0.44	-0.72	-0.28	-0.16	-0.72	-0.37	0.3	-0.48	0.36	0.34	-0.24	0.44	-0.24	0.26	-0.18	0.11	-0.34	-0.47	-0.49	-0.63	0.24		0.66
Short Term Investments	-0.73	-0.35	-0.67	-0.58	-0.73	-0.52	-0.34	-0.56	-0.61	0.4	-0.73	0.24	0.4	-0.79	-0.01	-0.43	0.69	-0.56	-0.28	-0.57	-0.42	-0.77	-0.5	0.83	0.66

Click cells to compare fundamentals

Lifecore Biomedical Account Relationship Matchups

Lifecore Biomedical fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	541.3M	502.9M	295.2M	295.4M	255.2M	248.0M
Short Long Term Debt Total	221.1M	221.4M	153.2M	153.1M	112.7M	65.2M
Other Current Liab	19.0M	20.3M	16.9M	17.1M	10.8M	12.6M
Total Current Liabilities	164.4M	101.9M	79.2M	79.4M	38.8M	55.0M
Total Stockholder Equity	231.0M	202.8M	107.9M	108.1M	(1.8M)	(1.7M)
Property Plant And Equipment Net	200.0M	217.7M	200.4M	139.0M	134.6M	78.2M
Net Debt	220.8M	220.1M	151.5M	151.4M	93.6M	98.3M
Retained Earnings	71.2M	38.6M	(58.9M)	(58.7M)	(176.2M)	(167.4M)
Accounts Payable	54.0M	51.6M	47.6M	15.8M	22.1M	23.6M
Cash	1.1M	360K	1.3M	1.6M	19.1M	10.9M
Non Current Assets Total	386.1M	384.2M	354.6M	171.4M	155.9M	161.1M
Non Currrent Assets Other	(9.7M)	(25.3M)	(26.7M)	3.0M	3.2M	3.4M
Cash And Short Term Investments	1.1M	360K	1.3M	1.6M	19.1M	13.4M
Common Stock Shares Outstanding	29.2M	29.3M	29.5M	29.5M	30.0M	26.2M
Liabilities And Stockholders Equity	541.3M	502.9M	295.2M	295.4M	255.2M	248.0M
Non Current Liabilities Total	145.9M	198.3M	108.0M	107.9M	218.2M	229.1M
Inventory	66.3M	69.7M	66.8M	67.0M	45.4M	26.8M
Other Current Assets	8.3M	14.2M	7.4M	7.1M	5.1M	8.8M
Other Stockholder Equity	160.3M	162.6M	165.5M	167.4M	174.3M	121.7M
Total Liab	310.3M	300.1M	187.2M	187.3M	257.0M	269.8M
Total Current Assets	157.1M	148.3M	123.7M	124.0M	99.3M	86.9M
Short Term Debt	61.8M	93.4M	32.9M	45.6M	1.8M	1.7M
Net Receivables	76.2M	70.0M	48.2M	48.3M	29.7M	35.3M
Intangible Assets	45.2M	38.1M	36.1M	15.6M	4.2M	4.0M
Current Deferred Revenue	499K	352K	1.1M	919K	4.1M	4.3M
Good Will	54.5M	76.7M	69.4M	13.9M	16.0M	15.2M
Accumulated Other Comprehensive Income	64K	(2.8M)	(1.4M)	(586K)	(39.2M)	(37.3M)
Other Liab	14.6M	11.3M	422K	3.5M	3.1M	3.0M
Net Tangible Assets	123.6M	143.2M	78.5M	(19.9M)	(17.9M)	(17.0M)
Other Assets	2.2M	157.7M	3.0M	3.2M	3.7M	3.5M
Long Term Debt	101.4M	164.9M	97.6M	101.3M	116.5M	121.5M
Capital Lease Obligations	30.8M	27.5M	15.0M	11.0M	9.9M	14.1M
Net Invested Capital	421.4M	396.7M	246.1M	99.9M	89.9M	85.4M
Short Long Term Debt	89.0M	29M	40.6M	488K	439.2K	417.2K
Non Current Liabilities Other	4.6M	3.6M	190K	3.1M	2.8M	2.1M
Net Working Capital	(7.3M)	46.4M	44.5M	60.5M	69.6M	73.0M
Property Plant Equipment	217.7M	137.4M	139.0M	134.6M	121.1M	132.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Lifecore Stock Analysis

When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Lifecore Cash And Short Term Investments vs Net Receivables Analysis

Cash And Short Term Investments vs Net Receivables

Cash And Short Term Investments vs Net Receivables Correlation Analysis

Correlation Coefficient

Cash And Short Term Investments

Net Receivables

Lifecore Biomedical fundamental ratios Correlations

Lifecore Biomedical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Lifecore Biomedical fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Additional Tools for Lifecore Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Assets Total	+ 0.99	Total Assets
Net Debt	+ 0.99	Short Long Term Debt Total
Net Receivables	+ 0.98	Total Assets
Inventory	+ 0.96	Short Long Term Debt Total
Retained Earnings	+ 0.96	Total Stockholder Equity

Common Stock	- 0.97	Common Stock Shares Outstanding
Short Term Investments	- 0.79	Common Stock Shares Outstanding
Short Term Investments	- 0.77	Net Receivables
Cash And Short Term Investments	- 0.77	Property Plant And Equipment Net
Cash	- 0.76	Property Plant And Equipment Net
Common Stock	- 0.74	Other Stockholder Equity